Spots Global Cancer Trial Database for Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy
Official Title: A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial Evaluating the Safety and Efficacy of A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial Evaluating the Safety and Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Cirrhotic Patients Scheduled to Undergo Partial Hepatectomy Due to Liver Cancer or Benign Tumours
Study ID: NCT01562821
Study Description
Brief Summary: This trial is conducted in Asia. The aim of this trial is to evaluate the haemostatic efficacy of activated recombinant human factor VII in cirrhotic patients scheduled to undergo partial hepatectomy due to liver cancer or benign tumours.
Detailed Description:
Keywords
Eligibility
Minimum Age: 21 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Novo Nordisk Investigational Site, Beijing, Beijing, China
Novo Nordisk Investigational Site, Shanghai, Shanghai, China
Novo Nordisk Investigational Site, Beijing, , China
Novo Nordisk Investigational Site, Taipei, , Taiwan
Novo Nordisk Investigational Site, Taipei, , Taiwan
Novo Nordisk Investigational Site, Bangkok, , Thailand
Novo Nordisk Investigational Site, Bangkok, , Thailand
Contact Details
Name: Global Clinical Registry (GCR, 1452)
Affiliation: Novo Nordisk A/S
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
